APC, antigen-presenting cell; Adoptive T cell therapy; CAR, chimeric antigen receptor; CD4, -8, -80, cluster of differentiation 4, -8, -80; CTL, cytotoxic-T lymphocyte; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; Cervical cancer; DC, dendritic cell; DFS, disease free survival; DNA, deoxyribonucleic acid; FIGO, International Federation of Gynecology and Obstetrics; HLA, human leucocyte antigen; HPV, human papilloma virus; Human papillomavirus; IL-2, interleukin 2; ILT's, Ig-like transcripts; Immune checkpoints inhibitors; LLO, listerolysin O; Lm, Listeria monocytogenes; MAGE-A3, melanoma-associated antigen 3; MCH, major histocompatibility complex; ORR, objective response rate; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PFS, progression free survival; RNA, ribonucleic acid; SLP, synthetic long-peptide; TCR, T-cell receptor; TGFß, transforming growth factor beta; TILs, tumor-infiltrating lymphocytes; TRAEs, treatment related adverse events; Therapeutic vaccines